Gelie Benniao Pian (格列本脲片)格列本脲片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 杭州爱大制药有限公司Chinese legal name: 杭州爱大制药有限公司
主要成分Active Ingredients
- 格列本脲Gelie Benniao
药物知识说明
格列本脲是一种在国家药监局注册认定的药品。该药品含有格列本脲-c021c01e等成分。
该药品关联的活性成分包括：格列本脲。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：杭州爱大制药有限公司Chinese legal name: 杭州爱大制药有限公司。
您可以探索含有相同成分的其他药品：格列本脲-c021c01e成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 格列本脲片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Manufacturers recorded for this product: 杭州爱大制药有限公司Chinese legal name: 杭州爱大制药有限公司.
Explore other medicines containing the same ingredient: 格列本脲 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 格列本脲片Recorded Chinese name: 格列本脲片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 2.5mg2.5 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 杭州爱大制药有限公司Chinese legal name: 杭州爱大制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H33020446
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H33020446
Manufacturer
Chinese legal name: 杭州爱大制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H33020446
生产企业
杭州爱大制药有限公司(国产)
适应症
本品适用于单用饮食控制疗效不满意的轻，中度Ⅱ型糖尿病，病人胰岛B细胞有一定的分泌胰岛素功能，并且无严重的并发症。
用法用量
1.口服，开始2.5mg，早餐前或早餐及午餐前各一次，轻症者1.25mg，一日三次，三餐前服，7日后递增每日2.5mg。 2.一般用量为每日5～10mg，最大用量每日不超过15mg。
不良反应
1.可有腹泻、恶心、呕吐、头痛、胃痛或不适。
2.较少见的有皮疹。
3.少见而严重的有黄疸、肝功能损害、骨髓抑制、粒细胞减少（表现为咽痛、发热、感染）、血小板减少症（表现为出血、紫癜）等。
禁忌
1.Ⅰ型糖尿病人。
2.Ⅱ型糖尿病人伴有酮症酸中毒、昏迷、严重烧伤、感染、外伤和重大手术等应激情况。
3.肝、肾功能不全者。
4.对磺胺药过敏者。
5.白细胞减少的病人。
注意事项
1.下列情况应慎用：体质虚弱、高热、恶心和呕吐、甲状腺功能亢进、老年人。
2.用药期间应定期测血糖、尿糖、尿酮体、尿蛋白和肝、肾功能，并进行眼科检查等。
贮藏
密封保存。
规格
2.5mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.